Side-by-side · Research reference

5-Amino-1MQvsDihexa

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongAUTO-DRAFTED8/38 cited

BAnimal-StrongHUMAN-REVIEWED7/28 cited

5-Amino-1MQ

NNMT inhibitor · Methylation / SAM modulation

100–200 mgDaily dose (oral)Neelakantan 2018

AnimalEvidence levelNeelakantan 2018

HoursHalf-life (est)

Oral · Once daily fasted

Dihexa

Angiotensin IV Analogue · Pre-Clinical

Pre-clinicalDevelopment stage

Rodent onlyEvidence basisBenoist 2014

HGF/c-MetTarget systemWright 2015

Not established — animal studies only

01Mechanism of Action

Parameter

5-Amino-1MQ

Dihexa

Primary target

Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018

c-Met receptor (HGF receptor tyrosine kinase)

Pathway

NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018

HGF/c-Met receptor activation → downstream signaling cascade → synaptogenesis and dendritic arborization

Downstream effect

Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018

Induction of dendritic arborization, synapse formation, neurogenesis, and neuroprotection in rodent models

Feedback intact?

—

Origin

Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018

Small-molecule angiotensin IV analogue designed to activate HGF/c-Met systemWright 2015

Antibody development

—

02Dosage Protocols

Parameter

5-Amino-1MQ

Dihexa

Standard dose

100–200 mg / day oralNeelakantan 2018

Anecdotal community range; murine doses scaled.

—

Frequency

Once daily, fasted

—

Lower / starter dose

50 mg / day

—

Evidence basis

Animal-strong; no human RCT dataNeelakantan 2018

Pre-clinical / Rodent models

Duration

8–12 weeks per cycle

—

Form

Oral capsule

—

Timing

Morning fasted preferred

—

Half-life

Hours (estimated; no human PK published)

—

Human dosing

—

Not established — no human trials

Animal studies

—

Mouse/rat models only — dosing not translatable to humans

Clinical status

—

No Phase 1, 2, or 3 trials published

04Side Effects & Safety

Parameter

5-Amino-1MQ

Dihexa

GI symptoms

Mild nausea (anecdotal)

—

Methylation disruption

Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)

—

Long-term safety

Unknown — no human trials

—

Cancer risk

Unclear — NNMT also studied in oncology contexts

—

Pregnancy / OB

Avoid

—

Drug interactions

Theoretical with niacin / B-vitamin supplements

—

Human safety data

—

None available — no human clinical trials

Theoretical c-Met risks

—

c-Met receptor activation has been implicated in tumorigenesis; unknown cancer risk profile

Pre-clinical tolerability

—

Not systematically reported in available studies

Absolute Contraindications

5-Amino-1MQ

·Pregnancy / breastfeeding
·Active malignancy

Dihexa

·Not approved for human use — research compound only

Relative Contraindications

5-Amino-1MQ

·Methylation-sensitive conditions (MTHFR mutation)
·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)

Dihexa

·Theoretical contraindication: active or history of malignancy (c-Met pathway involvement in cancer)

05Administration Protocol

Parameter

5-Amino-1MQ

Dihexa

1. Form

Oral capsule. No injection.

No established protocol. Dihexa has not been tested in human subjects. Animal studies used various routes (typically subcutaneous or intraperitoneal in rodents) not translatable to clinical use.

2. Administration

Take with water, fasted preferred.

Pre-clinical research compound. Not approved by FDA or any regulatory authority for human use.

3. Timing

Morning fasted.

—

4. Storage

Room temp ≤25 °C, dry place.

—

5. Caveat

Monitor B-vitamin status with chronic use.

—